OCERA THERAPEUTICS, INC.

REDWOOD CITY, CA How do I update this listing?

Ocera Therapeutics is based out of Redwood City. Tranzyme is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of acute (hospital-based) and chronic gastrointestinal (GI) motility disorders. GI motility disorders are conditions which disrupt the normal movement of food throughout the GI tract. Tranzyme��������s two most advanced product candidates, ulimorelin, which is in Phase 3, and TZP-102, which is entering Phase 2b, are being evaluated for the treatment of predominantly upper GI motility disorders. Approximately 20 percent of adults worldwide are affected by conditions these product candidates are designed to treat. While upper GI motility disorders are a highly prevalent group of persistent and recurring conditions, there are currently a limited number of treatment options for patients suffering from these conditions. In addition to ulimorelin and TZP-102, Tranzyme is also developing a motilin antagonist, TZP-201, for the treatment of various forms of moderate-to-severe diarrhea, and a ghrelin antagonist, TZP-301, for the treatment of obesity and other metabolic diseases.Whalewisdom has at least 155 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2013-11-21. The notice included securities offered of Equity,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security

Create Alert

Contact Info

ocera therapeutics, inc.
555 TWIN DOLPHIN DRIVE
REDWOOD CITY CA    94065

Business Phone: 6504750158
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS

Active Schedule 13D and 13G events

Sign in to see

Insider Transactions in the past year

Loading...

Form D Filings

Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2013-11-21 D BIOTECHNOLOGY Equity,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 28,000,000 28,000,000 0
2013-07-24 D PHARMACEUTICALS Option, Warrant or Other Right to Acquire Another Security,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security INDEFINITE 0 INDEFINITE
2013-07-16 D/A PHARMACEUTICALS Equity INDEFINITE 0 INDEFINITE
2013-07-16 D PHARMACEUTICALS Equity INDEFINITE 0 INDEFINITE
2013-07-16 D PHARMACEUTICALS Equity INDEFINITE 20,000,000 INDEFINITE
2010-06-24 D PHARMACEUTICALS Equity 3,000,000 2,000,000 1,000,000
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
AARON DAVIDSON subscription required
    DIRECTOR
ALEX ZISSON subscription required
    DIRECTOR
ANNE M. VANLENT subscription required
    EXECUTIVE OFFICER
BRENDA D. GAVIN subscription required
    DIRECTOR
DANA S. MCGOWAN subscription required
    EXECUTIVE OFFICER
DAVID J. DRUTZ subscription required
    DIRECTOR
DAVID S. MOORE subscription required
    EXECUTIVE OFFICER
DONALD F. CORCORAN subscription required
    DIRECTOR
ECKARD WEBER subscription required
    DIRECTOR
FRANCK S. ROUSSEAU subscription required
    EXECUTIVE OFFICER DIRECTOR
JEAN-PAUL CASTAIGNE subscription required
    DIRECTOR
JERYL L HILLEMAN subscription required
    EXECUTIVE OFFICER
LARS EKMAN subscription required
    DIRECTOR
LINDA S. GRAIS subscription required
    EXECUTIVE OFFICER DIRECTOR
MICHAEL F. POWELL subscription required
    DIRECTOR
NINA KJELLSON subscription required
    DIRECTOR
PRATIK SHAH subscription required
    DIRECTOR
RICHARD I. EISENSTADT subscription required
    EXECUTIVE OFFICER
VIPIN K. GARG subscription required
    EXECUTIVE OFFICER DIRECTOR

Elevate your investments